Skip to content

Depression in bipolar affective disorder

A comprehensive update on the diagnosis and management of depression as it occurs in bipolar affective disorder Bipolar affective disorder affects about 2 per cent of the population and is the sixth-leading cause of disability worldwide (Murray et al, 1997). It typically consists of both manic and depressive episodes separated by periods of normal mood.…

Read More

Psychiatry versus psychology

Psychologist or psychiatrist? Why you need both in your neurology service For many health professionals, as well as among the public, the roles of psychology and psychiatry are often unclear and difficult to distinguish. In addition, the relationship between psychology and psychiatry has historically been complex and sometimes conflictual (Costello and Angold, 2014).  This review…

Read More

Under 18s psychiatric treatment in Ireland – latest data

The latest figures from the HRB show an increase in the number of under 18s admitted to Irish psychiatric units and hospitals A recently published report by the Health Research Board (HRB) on the 2019 activities of the 66 approved psychiatric units and hospitals in Ireland, shows an increase in the number of under 18-year-olds…

Read More

Gastro-oesophageal reflux disease (GORD)

An overview of the risk factors, symptoms, and latest treatment approaches to GORD Gastro-oesophageal reflux disease (GORD) is a common disorder of the GI system. A higher incidence occurs in people living in western countries, affecting up to 20 per cent of the population. GORD is defined as “symptoms or complications resulting from the reflux…

Read More

Irritable bowel syndrome (IBS) in focus

A clinical overview of the characteristics of IBS and the various treatment options Irritable bowel syndrome (IBS) the most commonly-diagnosed gastrointestinal condition, can affect up to one-in-five people at some point in their lives. This could be an underestimation of the condition, as it is thought that many suffering with IBS do not seek medical…

Read More

Treating and managing Crohn’s disease and UC

Siún Tobin, MPSI Senior Pharmacist, Our Lady’s Hospice and Care Services. Specialising in cancer care, palliative care, and medicines information A clinical overview of Crohn’s disease and ulcerative colitis presentation and management strategies Crohn’s disease (CD) and ulcerative colitis (UC) are collectively known as inflammatory bowel disease (IBD). An estimated 40,000 people in Ireland live…

Read More

EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies

The European League Against Rheumatism (EULAR) has recently published recommendations for the management of patients with Sjögren’s syndrome with topical and systemic therapies.          The therapeutic management of Sjögren’s syndrome has not changed substantially in recent decades: Treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the…

Read More

Psoriatic arthritis — epidemiology, diagnosis and treatment

Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease of the joints and skin characterised by the presence of dactylitis, enthesitis, nail psoriasis and spondylitis. Clinical manifestations also include skin psoriasis, distal interphalangeal (DIP) arthritis, osteoperiostitis, oligoarthritis and arthritis mutilans. It is one of a group of disorders known as the spondyloarthropathies. PsA is variable…

Read More

Round-up of the most topical research presented at EULAR 2020

Study on Covid-19 in rheumatic/musculoskeletal diseases provides reassurance on medications A current study published in the run-up to the European Congress of Rheumatology of the EULAR analysed, for the first time, 600 Covid-19 cases in rheumatic disease patients from 40 countries and investigated the impact of the choice of rheumatic disease therapy on potential hospitalisation…

Read More

Side-effect management of anti-cancer immunotherapy agents

Immunotherapy is an anti-cancer therapy that attempts to reactivate the patient’s own immune system to recognise and target cancer cells. Immunological agents frequently seen in practice are pembrolizumab, nivolumab, ipilimumab, durvalumab, and atezolizumab but there are many more in development. The growing use of immunotherapy has led to an increased frequency of novel toxicities known…

Read More
Scroll To Top